COMP <GO>
INSP vs LMAT // GROSS PROFIT MARGIN
Inspire Medical Systems Inc. (NYSE) VS. LeMaitre Vascular Inc. (NASDAQ) • 15-METRIC TALLY: INSP 6
— LMAT 7
▲ GROSS PROFIT MARGIN LEADER: INSP
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
gross-margins
85.40%
LAST: $85.27 (+2.90%) • MKT CAP: $1.95B
gross-margins
71.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSP VS. LMAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSP | LMAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 85.40% | 71.50% | +13.90 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 14.70% | -8.70 | LMAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.3x | 28.3x | -5.00 | INSP | /valuation <GO> |
| Free Cash Flow Yield | 3.81% | 4.17% | -0.36 | LMAT | /fcf-yield <GO> |
| Operating Margin | 5.60% | 27.20% | -21.60 | LMAT | /operating-margins <GO> |
| Net Profit Margin | 15.90% | 23.10% | -7.20 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 13.50% | +0.10 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.93% | -0.93 | LMAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.40 | 7.30 | +4.10 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.5 | 56.2 | -2.70 | LMAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 28.4x | -16.50 | INSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.06B | $1.95B | $107.8M | INSP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSP REV | LMAT REV | INSP GROSS % | LMAT GROSS % | INSP FCF | LMAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $249.6M | 85.4% | 71.5% | $78.5M | $81.3M |
| FY 2024 | $802.8M | $219.9M | 84.7% | 68.6% | $91.1M | $44.1M |
| FY 2023 | $624.8M | $193.5M | — | — | $24.7M | $36.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSP // BETA —
LMAT // BETA —